KRIBIOLISA™ Benralizumab ELISA
Enzyme Immunoassay for the quantitative determination of Benralizumab in serum, plasma and cell culture supernatant
Receive your quote directly from the manufacturer.
Introduction:
Benralizumab is a monoclonal antibody is used for the treatment of asthma. It is directed against the alphachain of the interleukin-5 receptor (CD125). The humanized monoclonal antibody benralizumab specifically binds to IL-5Rα, thereby preventing the interaction between IL-5 and its receptor. In addition, through its Fc constant region, benralizumab binds to the FcγIIIRa receptor expressed by natural killer cells, thus inducing eosinophil apoptosis operated by the release of proapoptotic proteins such as granzymes and perforins.
Intended Use:
The KRIBIOLISA™ Benralizumab ELISA is used as an analytical tool for quantitative determination of Benralizumab in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Benralizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Benralizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Benralizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Benralizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
